ArticleBMC ophthalmology2025
Cefuroxime-related hemorrhagic retinal vasculitis following cataract surgery.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current landscape of drug induced retinal vasculitis.Journal of ophthalmic inflammation and infection · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntracameral cefuroxime is commonly used during cataract surgery to prevent postoperative endophthalmitis (POE). However, its association with rare complications, such as hemorrhagic occlusive retinal vasculitis (HORV), remains underreported. Reporting these cases is important to increase awareness of this rare but serious complication of intracameral cefuroxime in complicated cataract surgeries and to improve the understanding of its clinical presentation and potential risk factors.
methodWe retrospectively reviewed cataract surgeries performed at a tertiary center between 2015 and 2023. Records of patients with posterior capsule rupture (PCR), vitreous complications, or postoperative visual loss referred to the retina unit were analyzed. Hemorrhagic retinal vasculitis (HRV) was diagnosed based on clinical findings and fundus fluorescein angiography (FFA), and comprehensive ocular and systemic evaluations were performed to exclude other etiologies.
resultsDuring the study period, PCR occurred in 278 eyes, and intracameral cefuroxime prophylaxis at the standard dose (1 mg/0.1 mL) was administered in 245 of these eyes. Among the eyes treated with cefuroxime, three cases of HRV were identified. All presented with impaired vision in the early postoperative period. Fundus examination revealed diffuse retinal vascular occlusion, hemorrhages clustered along venules, and macular whitening, while FFA demonstrated hypofluorescent areas, widespread peripheral vascular occlusion, and ischemia. All patients underwent panretinal photocoagulation (PRP). One patient subsequently developed ocular neovascularization, rhegmatogenous retinal detachment, and phthisis bulbi; in the remaining two, no neovascularization was observed, although one developed optic atrophy.
conclusionsHRV may occur following intracameral cefuroxime at recommended doses in complicated cataract surgery with posterior capsule compromise. Surgeons should be aware of this rare but serious complication, particularly when posterior capsule integrity is compromised and the administered dose may reach the vitreous.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.